HCM (Hutchison MediPharma) Enterprise Value-to-Revenue Multiple

Public company logo of hutch-med.com (HCM)

HUTCHMED (HCM) proprietary plants and R&D centers operate at maximum efficiency, implementing GMP standards for global export. The company's EV/Revenue ratio helps monitor this trend, while the 1962.76 indicator reflects the status of the current valuation. The holding combines the development of oncology drugs with distribution in China to ensure financial stability, delegating clinical trials and marketing to external contractors.

Hutchison MediPharma - HCM Company Value to Revenue (period 11/23/2025 - 11/20/2026)

hutch-med.com - analytical breakdowns and key metrics (HCM)

- stock value and consensus price forecast:
Initial company analysis:HUTCHMED (China) Limited HCM
Product sample of HUTCHMED (China) Limited

The global commercialization of innovative drugs by HUTCHMED (HCM) relies on strategic partnerships, which directly impacts revenue growth rates. By analyzing the EV/Revenue multiple on GURU.Markets, an investor assesses the business value accounting for net debt to determine whether a low valuation results from fundamental stagnation or represents an entry point into an undervalued asset.

Competitor analysis for HUTCHMED (China) Limited